# altcoin / # bitcoin / # blockchain / # exchange / # events / # ICO / # trends / # finance / # Russian news

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

2024-11-12 05:44 pm NEWS
AbbVie’s “pain” is Bristol Myers Squibb’s “gain,” says Truist Securities analyst Srikripa Devarakonda.
Read The Rest at
marketwatch.com
abbvie disappointing schizophrenia trial bodes rival bristol myers analysts
SOURCE:

You May Also Like

1 Is the Signature the Same as a Transaction ID in Crypto?
Is the Signature the Same as a Transaction ID in Crypto?
2 What we know about Luigi Mangione, the Ivy League grad arrested and linked to UnitedHealthcare CEO's killing
What we know about Luigi Mangione, the Ivy League grad arrested and linked to UnitedHealthcare CEO's killing
3 Nvidia shares drop as China opens antimonopoly probe into US chip giant
Nvidia shares drop as China opens antimonopoly probe into US chip giant
4 Crypto Investor Boosts Holdings In $ai16z And $ZEREBRO, Secures $2.35M In Floating Profits
Crypto Investor Boosts Holdings In $ai16z And $ZEREBRO, Secures $2.35M In Floating Profits
5 How Soon Can XRP Price Cross ATH?
How Soon Can XRP Price Cross ATH?



© 2022 CRYPTONEWS
Cryptocurrency news – Bitcoin, etherium, altcoins, Blockchain, crypto exchange, law regulation | donate